14-day Premium Trial Subscription Try For FreeTry Free

BioMarin Pharmaceutical (BMRN) Q1 Earnings and Revenues Surpass Estimates

09:25pm, Wednesday, 27'th Apr 2022 Zacks Investment Research
BioMarin (BMRN) delivered earnings and revenue surprises of 44.74% and 2.82%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
BioMarin (BMRN) delivered earnings and revenue surprises of 44.74% and 2.82%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Drug/Biotech Stocks' Apr 27 Q1 Earnings Roster: GSK, AMGN & More

03:44pm, Tuesday, 26'th Apr 2022 Zacks Investment Research
Let us take a look at four drug/biotech companies, namely, GSK, AMGN, ALKS and BMRN, which are due to release their quarterly results on Apr 27.
Upgrades RBC Capital upgraded the previous rating for United States Steel Corp (NYSE:X) from Sector Perform to Outperform. United States Steel earned $3.64 in the fourth quarter, compared to $0.27 in

10 Biggest Price Target Changes For Monday

11:53am, Monday, 25'th Apr 2022 Benzinga
Keybanc cut Salesforce, Inc. (NYSE: CRM) price target from $281 to $223. Salesforce shares fell 1.1% to $169.60 in pre-market trading. Raymond James cut the price target for Avery Dennison Corporat

7 Potential Biotech Stocks Buyout Targets in 2022

08:10am, Thursday, 21'st Apr 2022
Big biopharma companies usually rely on M&A to get immediate access to a new class of drug or technology, fill in the gap in their pipeline and compensate for revenue loss from patent expiration of bl

Why Is BioMarin (BMRN) Up 4.6% Since Last Earnings Report?

03:30pm, Friday, 25'th Mar 2022 Zacks Investment Research
BioMarin (BMRN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
BioMarin (BMRN) reported earnings 30 days ago. What's next for the stock?

Sanofi's (SNY) Hemophilia A Candidate Meets Study Endpoints

03:26pm, Thursday, 10'th Mar 2022 Zacks Investment Research
Sanofi (SNY) and Sobi's factor VIII replacement therapy candidate, efanesoctocog alfa, achieves clinically meaningful prevention of bleeds in people with severe hemophilia A

BioMarin: Keep Waiting For The Growth

09:43pm, Thursday, 03'rd Mar 2022 Seeking Alpha

BioMarin: Keep Waiting For The Growth

04:43pm, Thursday, 03'rd Mar 2022
BioMarin released positive financials, but investors were disappointed by some clinical trial data.

Why BioMarin Pharmaceutical Tumbled on Thursday

10:09pm, Thursday, 24'th Feb 2022 The Motley Fool
While the company broadly met expectations for the fourth quarter, investors seemed concerned about its 2022 guidance.

Why BioMarin Pharmaceutical Tumbled on Thursday

10:09pm, Thursday, 24'th Feb 2022 The Motley Fool
While the company broadly met expectations for the fourth quarter, investors seemed concerned about its 2022 guidance.

Why BioMarin Pharmaceutical Tumbled on Thursday

05:09pm, Thursday, 24'th Feb 2022
While the company broadly met expectations for the fourth quarter, investors seemed concerned about its 2022 guidance.

BioMarin (BMRN) Q4 Earnings Top Estimates, Sales Fall Y/Y

03:50pm, Thursday, 24'th Feb 2022 Zacks Investment Research
Biomarin Pharmaceutical's (BMRN) fourth-quarter earnings and sales beat estimates. Stock declines
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE